Skip Navigation

Annals of Oncology 2005 16(12):1853-1854; doi:10.1093/annonc/mdi413
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Douillard, J. Y.
Right arrow Articles by Bennouna, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Douillard, J. Y.
Right arrow Articles by Bennouna, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Editorial

Adjuvant chemotherapy for colon cancer: a confusing area!

J. Y. Douillard* and J. Bennouna

Division of Medical Oncology, Centre R. Gauducheau, Bd J. Monod, 44805 St-Herblain, France

* E-mail: jy-douillard@nantes.fnclcc.fr

The first 150 words of the full text of this article appear below.

The curability of colon cancer has greatly improved in the past 15 years with the introduction of 5-fluorouracil (5-FU)/leucovorin (LV)-based adjuvant chemotherapy. The last study with a surgery-alone control arm, published by Moertel et al. [1Go] in 1990, showed that surgery alone in stages II and III cured 55% of patients whereas the addition of 6 month 5-FU/levamisole improved 3.5-year survival up to 71%. For stage III, these figures for recurrence-free survival were 47% for surgery alone and 63% with adjuvant chemotherapy (P <0.0001). Various regimens have been evaluated since and the bolus 5-FU/LV known as Mayo Clinic has been a reference treatment for years, along with the weekly bolus 5-FU/LV known as Roswell Park. In 2003, the French cooperative group GERCOR [2Go] demonstrated that an infusional, 48-h regimen, in combination with LV, had a similar efficacy to the bolus Mayo Clinic regimen, but a better safety . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
C. J. A. Punt, M. Buyse, C.-H. Kohne, P. Hohenberger, R. Labianca, H. J. Schmoll, L. Pahlman, A. Sobrero, and J.-Y. Douillard
Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon Cancer and Proposed Definitions for Future Trials
J Natl Cancer Inst, July 4, 2007; 99(13): 998 - 1003.
[Abstract] [Full Text] [PDF]